Evidence map›Paper›PMID 34942685›Full record

ArticleCancer research and treatment2022

The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer.

In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon Ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

In Hye SongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Young-Ae KimNeogenTC Corp., Seoul, Korea.
Sun-Hee HeoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Won Seon BangDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hye Seon ParkNeogenTC Corp., Seoul, Korea.
Yeon Ho ChoiNeogenTC Corp., Seoul, Korea.
Heejae LeeNeogenTC Corp., Seoul, Korea.
Jeong-Han SeoNeogenTC Corp., Seoul, Korea.
Youngjin ChoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sung Wook JungDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hee Jeong KimDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sei Hyun AhnDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hee Jin LeeDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Gyungyub GongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Neogen (United States) · USAsan Medical Center · KRUlsan College · KRUniversity of Ulsan · KR

Funding

NCIRD CDC HHS H23 IP000732
6 · The paper itself

Abstract

purposeThe expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, MHC I expression, level of tumor-infiltrating lymphocytes (TILs), and expression of interferon (IFN) mediator MxA are positively associated with one another in human breast cancers. This study aimed to investigate the mechanisms of association of MHC I with ER and IFN signaling. MATERIALS AND

methodsThe human leukocyte antigen (HLA)-ABC protein expression was analyzed in breast cancer cell lines. The expressions of HLA-A and MxA mRNAs were analyzed in MCF-7 cells in Gene Expression Omnibus (GEO) data. ER and HLA-ABC expressions, Ki-67 labeling index and TIL levels in tumor tissue were also analyzed in ER+/ human epidermal growth factor receptor 2 (HER2)- breast cancer patients who randomly received either neoadjuvant chemotherapy or estrogen modulator treatment followed by resection.

resultsHLA-ABC protein expression was decreased after β-estradiol treatment or hESR-GFP transfection and increased after fulvestrant or IFN-γ treatment in cell lines. In GEO data, HLA-A and MxA expression was increased after ESR1 shRNA transfection. In patients, ER Allred score was significantly lower and the HLA-ABC expression, TIL levels, and Ki-67 were significantly higher in the estrogen modulator treated group than the chemotherapy treated group.

conclusionMHC I expression and TIL levels might be affected by ER pathway modulation and IFN treatment. Further studies elucidating the mechanism of MHC I regulation could suggest a way to boost TIL influx in cancer in a clinical setting.

Indexed as

Breast NeoplasmsEstrogensFemaleFulvestrantHLA-A AntigensHLA AntigensHumansInterferonsKi-67 AntigenReceptors, EstrogenRNA, Small InterferingEstrogensFulvestrantHLA-A AntigensHLA AntigensInterferonsKi-67 AntigenReceptors, EstrogenRNA, Small InterferingBreast neoplasmsEstrogensInterferonsMajor histocompatibility complexReceptorsTumor-infiltrating lymphocytes

Identifiers

PMID34942685
PMCPMC9582481
OpenAlexW4225965627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.